Sergey Suchkov
A new systems approach to diseased states and wellness result in a new branch in the healthcare services, namely, personalized and precision medicine (PPM). Meanwhile, the era of genomics-based medicine and thus genomics biomarkers promises to provide molecular tests that will permit PPM as applicable to personalized & precision oncology (PPO).
Using the PCL-5 questionnaire and according to the DSM-5 criteria for PTSD, 20% were To achieve the implementation of PPM-guided oncology concept, it is necessary to create a funda-mentally new strategy based upon the subclinical recognition of biopredictors (including genomics ones) of hidden abnormalities (pre-cancer conditions) long before the disease clinically manifests itself. ).
Every human has a unique genetic makeup that causes them to respond differently to cancer. In this context, the genomic profiling can be done using genomic, transcriptomic, epigenomic or meta-genomic information, and will look at the genetic structure of the tumor. This helps us discover “ac-tionable” mutations that can be targeted with therapy. These discoveries can lead to new treatment recommendations that may effectively treat your cancer on a personalized level. Through those analyses, we can not only diagnose and classify cancer patients and/or pre-cancer persons-at-risk based on their comparative risk, but also monitor their response to emerging canonical, preventive or prophylactic therapies. Continued progress using these methods will transform how we approach treatment modalities for cancer patients.
The advent of next generation sequencing (NGS) and GWAS technologies has advanced our under-standing of the intrinsic biology of different tumor types. Prospective randomized clinical trials will determine whether matching actionable aberration with targeted therapy will contribute to improve survival in patients with malignancies.
PPM globally holds great promise, especially in cancer therapy and control, where PPO would allow practitioners to use this information to optimize the targeted treatment of a patient. PPO for groups of individuals would also allow for the use of population group specific diagnostic or prognostic cancer biomarkers. The integration of PPM-guided genomics into clinical practice is transforming treatment paradigms. Identification of oncogenes and tumor suppressor genes can become the stim-ulus for rational design of novel, selective drugs that execute specific activity directed at underlying genetic aberrations. This information can be used to track the progress of cancer, and to establish the molecular basis for drug resistance and allow the targeting of the genes or pathways responsible for drug resistance.
